Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078697 | 0.84 | DRD4 (0.43) | DRD4DRD3KMT2AL3MBTL1CYP11B1 | |
| SCHEMBL16877234 | 0.81 | RAB9A (0.41) | DRD4DRD3KMT2AL3MBTL1TAAR1 | |
| SCHEMBL7757122 | 0.81 | KDM5A (0.43) | KMT2AL3MBTL1CYP19A1ALDH1A1KCNH2 | |
| SCHEMBL21000906 | 0.79 | LTA4H (0.47) | ALDH1A1 | |
| SCHEMBL18420442 | 0.76 | KDM4C (0.47) | KMT2AL3MBTL1ALDH1A1APOBEC3G | |
| SCHEMBL332692 | 0.74 | DRD4 (0.44) | DRD4DRD3KCNH2 | |
| SCHEMBL859845 | 0.71 | — | — | |
| SCHEMBL10440332 | 0.71 | KCNH2 (0.43) | DRD4DRD3KMT2AALDH1A1APOBEC3G | |
| SCHEMBL7755878 | 0.71 | LTA4H (0.56) | CYP19A1HRH3 | |
| SCHEMBL25156787 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | DRD4 3597/4885DRD3 3560/4885HTR1D 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.